Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Mar;99(3):502-504.
doi: 10.1002/ajh.27219. Epub 2024 Jan 25.

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

Maria Gavriatopoulou  1 , Ioannis Ntanasis-Stathopoulos  1 , Panagiotis Malandrakis  1 , Despina Fotiou  1 , Magdalini Migkou  1 , Foteini Theodorakakou  1 , Vasiliki Spiliopoulou  1 , Nikolaos Kanellias  1 , Evangelos Eleutherakis-Papaiakovou  1 , Maria Roussou  1 , Giorgos Psarros  2 , Efstathios Kastritis  1 , Meletios A Dimopoulos  1 , Evangelos Terpos  1
Affiliations
Free article
Clinical Trial

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

Maria Gavriatopoulou et al. Am J Hematol. 2024 Mar.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate Belantamab Mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889-911.
    1. Ailawadhi S, Ma Q, Jalbert JJ, et al. Prevalence of ocular comorbidities in elderly patients with multiple myeloma in the US: an analysis of 100% Medicare sample data during 2007-2020. Blood. 2022;140(Supplement 1):5272-5273.
    1. Abeykoon JP, Vaxman J, Patel SV, et al. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022;199(1):95-99. doi:10.1111/bjh.18298
    1. de la Rubia J, Alonso R, Clavero ME, et al. Belantamab Mafodotin in patients with relapsed/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain. Cancers (Basel). 2023;15(11):2964. doi:10.3390/cancers15112964
    1. Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, et al. Real-world effectiveness and safety of Belantamab Mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023;24(14):11829. doi:10.3390/ijms241411829

MeSH terms

Associated data